PCSK9 Inhibitors

Chemical inhibitors of PCSK9 can function through various mechanisms to inhibit its activity, which is primarily the degradation of LDL receptors (LDLR). Berberine acts by upregulating LDLR expression, leading to an increased clearance of LDL cholesterol. This activity indirectly relates to PCSK9's function because PCSK9's primary role is to target LDLR for lysosomal degradation, and by increasing LDLR expression, Berberine ensures more receptors are available to clear LDL from the bloodstream. Similarly, Epigallocatechin gallate, a constituent of green tea, reduces PCSK9 expression in hepatocytes, thereby increasing the number of available LDL receptors. By elevating LDLR levels, this polyphenol indirectly inhibits the function of PCSK9. Specific flavonoids, such as naringenin, have been reported to decrease the ability of PCSK9 to bind LDL receptors, therefore inhibiting PCSK9's function in promoting LDLR degradation. Phloretin interferes with PCSK9's interaction with LDLRs, which can prevent the internalization and degradation of these receptors, hence indirectly inhibiting PCSK9.

Moreover, compounds like Luteolin, Quercetin, Rutin, and Dihydrotanshinone I have been implicated in mechanisms that maintain or increase LDL receptor levels on the cell surface. Luteolin leads to upregulation of LDLR synthesis, opposing PCSK9's regulatory role. Quercetin and Rutin both interfere with PCSK9's ability to mediate LDLR degradation, while Dihydrotanshinone I specifically inhibits the effect of PCSK9 on LDL receptor degradation. Ursolic acid, another chemical inhibitor, increases LDLR expression, which in turn inhibits PCSK9's role in LDL receptor degradation. Oleuropein and Rosmarinic acid are also involved in upregulating LDLR levels, indirectly inhibiting the LDL receptor degradation function of PCSK9. Lastly, Curcumin increases LDLR expression, which can help maintain higher levels of LDL receptors in the presence of PCSK9, thus inhibiting its function. Each of these chemicals targets the PCSK9 pathway by ensuring more LDL receptors are present on the cell surface, which counteracts the natural degradation process mediated by PCSK9.